INNOPHARMA INC. APPOINTS VISH SHETTY AS VICE PRESIDENT, BUSINESS DEVELOPMENT & ALLIANCE MANAGEMENT

PISCATAWAY, NJ, Nov. 11, 2013 (GLOBE NEWSWIRE) -- InnoPharma, Inc. today announced the appointment of Vish Shetty to the role of vice president, business development & alliance management. Mr. Shetty has over 10 years of extensive experience in market research, portfolio management, marketing, product launches, business development and strategic planning with pharmaceutical companies.

Commenting on the appointment, Navneet Puri, Ph.D., president & CEO of InnoPharma, stated, "The depth and breadth of Vish's generic and specialty pharmaceutical experience and expertise with injectable products will be a crucial asset to InnoPharma as we seek to progress to the next phase of our growth and development. We look forward to working with Vish as we continue to build our business and execute on our goals."

Prior to joining InnoPharma, Mr. Shetty held various roles in marketing, strategy, market research and portfolio management with Fresenius Kabi, Baxter and Hospira. Mr. Shetty received a Bachelor of Pharmacy from Poona College of Pharmacy, Master of Science degrees in pharmacy administration and management information systems from the University of Illinois at Chicago and an MBA from the Lake Forest Graduate School of Management.

About InnoPharma, Inc.
InnoPharma is a sterile product development company, focused on developing complex generic and innovative products in injectable and ophthalmic dosage forms. The Company has a broad portfolio of products under development, with formulations including solutions, suspension, lyophilized, emulsions, liposomes, micelles and lipid complexes. InnoPharma's pipeline includes small molecules with solubility and stability challenges, as well as difficult to produce and characterize polypeptides and carbohydrates. The Company has a comprehensive infrastructure for the development of its products in its state of the art R&D facilities in New Jersey, with the capability to handle potent and cytotoxic molecules. More information can be found at www.innopharmainc.com.